wechat public accounts

Address: Building F2, No. 88, Kechuang 6th Street, Beijing Economic Development Zone

Tel: +86  010-56315466

Fax: +86  010-56315314

E-mail: hr@jacobiopharma.com





Copyright: Jacobio Pharmaceuticals Co., Ltd.   Beijing ICP preparation 17065868-1   


Page view:

  Jacobio focuses on the areas of high unmet medical need like cancer, and leverages its expertise to provide new treatment options for patients. Through in-house R&D and partnerships with academic and industry experts, we have been establishing an innovative product pipeline consisting of small-molecule agents and antibody products.

  Jacobio’s leading drug candidate, JAB-3068, a SHP2 inhibitor, is being evaluated in phase IIa clinical trials for the treatment of patients with solid tumors. It has been granted orphan drug designation (ODD) from FDA for the treatment of patients with esophageal cancer. In 2019, Jacobio’s JAB-3312, an oral small-molecule anti-tumor agent, has been approved for clinical study by FDA and NMPA. At present, the clinical projects has carried out clinical trials in 25 research institutions in China and the United States.

  Clinical programs

  Preclinical programs